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ABSTRACT 
Purpose: To evaluate the biochemical freedom from failure (bFFF) by risk group and treatment modality and the 
predictive factors of bFFF by risk group in patients with prostate cancer undergoing permanent seed implantation (PI) 
with or without external beam radiation therapy (EBRT) in a nationwide prospective cohort study in Japan (J-POPS) 
during the first 2 years. 
Methods and Materials: The analyses included 2,316 participants in 42 institutions. bFFF was evaluated using the 
Phoenix definition and calculated using the Kaplan–Meier method, with factors compared using the Cox proportional 
hazard model. 
Results: Median follow-up period was 60.0 months. The 5-year bFFF rates in all patients, 1,028 low-risk, 1,114 
intermediate-risk, and 133 high-risk patients were 93.6%, 94.9%, 92.7%, and 91.1%. The 5-year bFFF rates in PI group 
and EBRT combination therapy group were 93.7% and 93.3%. On multivariate analysis, younger age, higher Gleason 
score (GS), higher percent positive biopsies (%PB), and lower prostate V100 (p=0.0012, 0.0030, 0.0026, and 0.0368) in 
all patients; younger age, higher pretreatment PSA, and lower prostate V100 (p=0.0002, 0.0048, and 0.0012) in low-risk; 
higher GS, higher %PB, and no hormonal treatment (HT) (p=0.0005, 0.0120, and 0.0022) in intermediate-risk; and higher 
GS and higher %PB (p=0.0329 and 0.0120) in high-risk patients were significantly associated with biochemical failure. 
Conclusions: PI with or without EBRT resulted in excellent short-term biochemical outcomes in all risk groups, 
especially in high-risk patients. Age, pretreatment PSA, and prostate V100 in low-risk; GS, %PB, and HT in 
intermediate-risk; GS and %PB in high-risk patients independently affected bFFF. 
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INTRODUCTION 
Permanent seed implantation (PI) with or without external beam radiation therapy (EBRT) has become a popular 
treatment option for patients with localized prostate cancer (PCa), with long-term local and biochemical control similar to 
outcomes observed after radical prostatectomy or EBRT (1, 2). 
   The number of patients with PCa treated with PI has rapidly increased in Japan, with over 37,000 patients treated 
through 2016 in 110 institutions (3, 4). To evaluate the safety and efficacy of PI in combination with or without EBRT 
and hormonal treatment (HT) for patients with localized PCa, a nationwide prospective cohort study entitled the Japanese 
Prostate Cancer Outcome Study of Permanent Iodine-125 (I-125) Seed Implantation (J-POPS; NCT00534196) was 
initiated in July 2005 (5). The enrollment of the participants for this study has started in July 2005 and continued until 
December 2010. Finally, 6,927 participants in 46 institutions had been registered. This study is the world’s largest 
registration study on PI.  
Ito et al. reported the biochemical relapse-free survival (bRFS) using the Phoenix definition and the newly developed 
J-POPS definition, overall survival, and the associated factors of bRFS among all patients in the J-POPS study who were 
registered during the first 2 years: cohort 1 (3). In this study, we evaluate the biochemical freedom from failure (bFFF) by 
risk group and treatment modality and the associated factors of bFFF by risk group in the same participants. 
 
METHODS AND MATERIALS 
Although the J-POPS study design has been previously described in detail (3, 5), a brief description of methods and 
materials is outlined below. 
 
 
 
Patient eligibility 
All participants were histologically confirmed as having adenocarcinoma of the prostate who were planning to 
undergo treatment with PI using loose I-125 seeds. Inclusion and exclusion criteria of the participants followed the 
recommendations of the American Brachytherapy Society (6). 
A total of 2,354 participants were enrolled in this study during the first 2 years. Out of the 2,354 participants, 
background characteristics and baseline data were available in 2,316 patients. Patients were divided into risk groups 
based on the presenting clinical characteristics. The low-risk group was defined as having the following characteristics: 
prostate-specific antigen (PSA) level less than 10 ng/mL, Gleason score less than or equal to 6, and clinical T stage less 
than or equal to T2a. The intermediate-risk group included one or more of the following features: PSA level of 10–20 
ng/mL, Gleason score of 7, and clinical T stage of T2b–T2c. The high-risk group included one or more of the following 
features: PSA level greater than 20 ng/mL, Gleason score of 8–10, and clinical T stage of T3a. Locally advanced was 
defined as clinical T stage T3b–T4. The distribution among risk groups was as follows: 1,028 (44.4%) patients in low-risk 
group, 1,113 (48.1%) patients in intermediate-risk group, 133 (5.7%) patients in high-risk group, 2 patients in locally 
advanced PCa group, and 21 (0.9%) patients in a group whose PCa was localized but with unknown risk classification. 
 
Treatment design 
The prescription dose for patients undergoing PI alone without combined EBRT was 144 Gy. The clinical target 
volume was defined as the prostate volume including an added treatment margin of 3–5 mm in all directions, except for 
less than 2 mm in the posterior direction. For EBRT combination therapy group, the recommended prescribed dose for PI 
was 100–110 Gy and that for EBRT was 40–50 Gy with 1.8–2.0 Gy/fraction. As for EBRT, the target volume consisted of 
the prostate gland, seminal vesicles, small pelvis, and/or whole pelvis.  
Computed tomography images, taken at 1–3-mm slice width, were obtained approximately 1 month after PI 
 
 
(interquartile range, 27–33 days) for postimplant dosimetric evaluation. The biologically effective dose (BED) was 
calculated from the values of the minimal dose received by 90% of the prostate volume (D90) and the EBRT dose using 
α/β = 2 Gy, applying the formulas described previously (7). 
Patient information is shown in Tables 1 and 2. 
 
The definition of biochemical relapse and follow-up protocol 
The Phoenix definition PSA failure definition ((PSA nadir + 2.0 ng/mL) was used to define bFFF (8).  For patients 
who failed by the Phoenix definition, if the PSA level subsequently decreased to less than or equal to 0.5 ng/mL without 
intervention, we considered it a PSA bounce. The event used to estimate the bFFF was PSA failure or clinical relapse if it 
occurred earlier than the PSA failure. Patients who survived without apparent PSA failure or clinical relapse at the last 
follow-up and those who died due to other causes were censored. 
The scheduled follow-up assessments included PSA blood tests and physical examinations every 3 months for the first 
2 years and every 6 months thereafter for 5 years after the completion of radiation therapy.  
 
Statistical analysis 
The Kaplan-Meier method was used to estimate the bFFF. The Cox proportional hazards model was also used to 
identify the factors associated with the bFFF. Patient age, pretreatment PSA, percent positive biopsies, prostate volume, 
the percent volumes of the prostate receiving 100% of the prescribed dose (V100), prostate D90, and BED were 
considered continuous variables, and risk group (low, intermediate, or high), Gleason score (GS) (6 or less, or 7 [3+4], or 
7 [4+3], 8 to 10 in all, low-risk, and intermediate-risk patients and 7 or less, or 8, or 9 in high-risk patients), clinical stage 
(T1c–T2a or T2bc–T3), treatment modalities (PI or PI with EBRT), and HT were considered the categorical variables. 
Probability (p) values of less than 0.05 were considered to be significant. A multivariate analysis was performed to 
analyze the factors that were found to be significantly associated with the bFFF in the univariate analysis.  
 
 
Statistical analyses were performed using SAS 9.3 statistical software (SAS Institute Inc., Cary, NC, USA). All 
statistical analyses were performed at the Translational Research Informatics (TRI) Center in the Foundation for 
Biomedical Research and Innovation, a public interest incorporated foundation. 
 
Ethical considerations 
The Ethical Review Committee of the TRI (Approval no. 05-01; May 6, 2005) and all of the institutional review 
boards of the participating facilities approved the study. 
 
RESULTS 
The median follow-up period was 60.0 months (interquartile range, 58.7–60.9 months). 
Biochemical relapse was observed in 140 patients (6.0%) in all patients, 51 patients (5.0%) out of the 1028 low-risk 
patients, 75 patients (6.7%) out of the 1114 intermediate-risk patients, and 11 patients (9.7%) out of the 133 high-risk 
patients. The 5-year bFFF rates in all, low-risk, intermediate-risk, and high-risk patients were 93.6%, 94.9%, 92.7%, and 
91.1%, respectively (Fig. 1). 
The 5-year bFFF rates in PI group and EBRT combination therapy group were 93.7% and 93.3%, respectively (Fig. 
1). 
Table 3 shows the factors that were found to be significantly associated with the bFFF in the univariate analysis and 
the results of the multivariate analysis for the effect of various factors on the bFFF in all, low-risk, intermediate-risk, and 
high-risk patients, respectively. On a multivariate analysis, younger age, higher Gleason score (GS), higher percent 
positive biopsies, and lower prostate V100 (p=0.0012, 0.0030, 0.0026, and 0.0368, respectively) in all patients; younger 
age, higher pretreatment PSA, and lower prostate V100 (p=0.0002, 0.0048, and 0.0012, respectively) in low-risk patients; 
higher GS, higher percent positive biopsies, and no HT (p=0.0005, 0.0120, and 0.0022, respectively) in intermediate-risk 
 
 
patients; and higher GS and higher percent positive biopsies (p=0.0329 and 0.0120, respectively) in high-risk patients 
were significantly associated with biochemical failure.  
 
DISCUSSION 
  The J-POPS study is the prospective cohort study on PI with the world’s largest registration. In this study, we 
evaluated the bFFF and treatment modality and the associated factors of bFFF by risk group among patients in the 
J-POPS study who were registered during the first 2 years. 
The 5-year bFFF or bRFS rates using the Phoenix definition were reported to be 92.1–98.6% in low-risk patients 
treated with PI monotherapy with or without HT (8–19), 86.0–97.3% in intermediate-risk patients treated with PI 
monotherapy with or without HT (10–14, 16, 18–23), and 78–95.2% in high-risk patients treated with EBRT combination 
therapy with or without HT (12, 16, 18, 19, 24–29), respectively. In our study, for the low-risk patients, 98.35% of the 
patients were treated with PI monotherapy and 39.40% of the patients received HT, and their 5-year bFFF rate was 94.9%. 
For the intermediate-risk patients, 62.93% of the patients were treated with PI monotherapy and 54.49% of the patients 
received HT, and their 5-year bFFF rate was 92.7%. For the high-risk patients, 82.71% of the patients were treated with 
EBRT combination therapy and 80.45% of the patients received HT, and their 5-year bFFF rate was 91.1%. Our outcomes 
in low-risk and intermediate-risk patients were similar to those in the other studies. 
Although Okamoto et al. reported their 5-year bFFF rate was 95.2% in high-risk patients, which was exceptionally 
high (28), our outcome in high-risk patients was relatively favorable as compared with the outcomes in the other studies. 
We assume that this may be attributable to the higher rate of high-risk patients who received HT. The rate of high-risk 
patients who received HT was 80.45% in our study. Zimmermann et al. reported that the rate of high-risk patients who 
received HT was 60.4%, and their 5-year bFFF rate was 79.2% in high-risk patients (12). Ohashi et al. reported that the 
rate of high-risk patients who received HT was 49.0%, and their 5-year bFFF rate was 84.8% in high-risk patients (27). 
 
 
Conversely, Okamoto et al. reported that the rate of high-risk patients who received HT was 100%, and their 5-year bFFF 
rate was 95.2% in high-risk patients (28). Additionally, this might be explained by the lower rate of patients with stage 
T3+ in all high-risk patients than the other studies. In our study, the rate of patients with stage T3+ in all high-risk patients 
was 12.03%. Riaz et al. reported that the rate of patients with stage T3+ in all high-risk patients was 33.3%, and their 
5-year bFFF rate was 78% in high-risk patients (26). Kauffmann et al. reported that the rate of patients with stage T3+ in 
all high-risk patients was 42.1%, and their 5-year bFFF rate was 82% in high-risk patients (21).  
In our study, younger age was significantly associated with biochemical failure only in low-risk patients. Some 
studies have reported the significantly worse biochemical outcomes of PI for younger patients (9, 30, 31). Others have 
reported that age was not associated with biochemical failure in low-risk patients (30, 32, 33, 34, 35). The relationship 
between younger age and more aggressive clinical behavior of PCa has been previously documented (36), and there is 
evidence that young-age PCa has several biological and genetic features, distinct from elderly-onset PCa (37). Because of 
the low BED and the low rate of patients who received HT in low-risk patients (Table 1, 2), aggressive PCa may not have 
been controlled. Furthermore, the number of low-risk patients was large in our study. Therefore, younger age may have 
been a significant factor associated with biochemical failure in low-risk patients. 
   Higher pretreatment PSA was also significantly associated with biochemical failure only in low-risk patients. Higher 
pretreatment PSA is reported to be significantly associated with biochemical failure in PI (38, 39). The two studies that 
analyzed the factors associated with biochemical failure by low-, intermediate-, and high-risk group, respectively, in the 
same group of PCa patients treated with PI reported that higher pretreatment PSA was significantly associated with 
biochemical failure only in low-risk patients (30, 32). These associations only in low-risk patients are consistent with our 
result. However, the reason is unclear. 
   Lower prostate V100 and D90 were also significantly associated with biochemical failure only in low-risk patients. 
Lower prostate D90 is reported to be significantly associated with biochemical failure in PI also in low-risk patients (34, 
 
 
35, 40). Lower prostate V100 is reported to be significantly associated with biochemical failure in PI in low-risk plus 
intermediate-risk patients (41, 42). Because of the low rate of patients who received HT or EBRT in low-risk patients 
(Table 1, 2), the prostate dose of PI may have had a strong effect on the local control. 
   No HT was significantly associated with biochemical failure only in intermediate-risk patients in our study. The 
efficacy of HT has not been established yet for patients with intermediate-risk disease (43). Some studies have reported 
that the use of HT was significantly associated with the bFFF in intermediate-risk patients (44, 45), whereas others have 
reported that the use of HT was not significantly associated with the bFFF in intermediate-risk patients (20, 32, 43, 46, 
47). The use of HT was not associated with bFFF in high-risk patients. Some studies have reported that the use of HT was 
significantly associated with the bFFF in high-risk patients (32, 48), whereas others have reported that that the use of HT 
was not significantly associated with the bFFF in high-risk patients (27, 47). The American College of Radiology 
Appropriateness Criteria (49) and the American Society of Clinical Oncology/Cancer Care Ontario joint guideline (50) 
recommend that high-risk patients treated with PI should receive supplemental EBRT and HT. High-risk patients actually 
often receive trimodality treatment method with PI, EBRT, and HT (24, 28, 30). In the absence of a controlled predefined 
set of criteria that establish which patients, what duration of HT, and which agents to be administered in our study, it is 
difficult to draw any firm conclusions about HT. 
   Higher percent positive biopsies was significantly associated with biochemical failure in intermediate-risk and 
high-risk patients. Some studies have reported significantly worse biochemical outcomes of PI in patients with higher 
percent positive biopsies in low-risk plus intermediate-risk (42, 51, 52), intermediate-risk plus high-risk (53, 54), and 
high-risk (27, 55) patients. Other studies have reported that a positive biopsy rate was not associated with biochemical 
failure in low-risk (35) and intermediate-risk (35, 43) patients. Many studies reported that higher percent positive biopsies 
has been correlated with a higher likelihood of extracapsular extension (56–60). Because of the lower percent positive 
biopsies, the probably low rate of extracapsular extension, and the low standard deviation of percent positive biopsies in 
 
 
low-risk patients (Table 1), the percent positive biopsies may have not been a factor associated with biochemical failure. 
   Our study evaluated the bFFF rate by risk group and treatment modality and the various associated factors of bFFF 
by risk group in J-POPS patients. Our study reported the significantly worse biochemical outcomes of PI for younger 
patients in low-risk patients for the first time. They should provide the helpful information concerning the treatment 
selection and the follow-up after PI for Japanese PCa patients. 
    The limitation of this study included the following: the discrepancies in Gleason scores among the institutions 
included in our study, absence of unified treatment modalities, presence of interobserver variability in postimplant 
dosimetry, and the biochemical failures that were initially judged by the physicians in each institution. To minimize 
interinstitutional variability in the GS in the J-POPS study, representative urologic pathologists in Japan conducted annual 
intensive lectures on the Gleason scoring system for general pathologists between 2004 and 2013 (3). Because the 
training workshops including the technical instruction of postimplant dosimetry are being held annually in Japan (4) and 
all the institutions in this study have participated in the workshops, interobserver variability in postimplant dosimetry 
should be minimized. Finally, the biochemical failures initially judged by the physicians in each institution were 
subsequently confirmed as appropriate by the specific committee that reviews biochemical failure in the J -POPS study 
(3).  
   The use of bFFF is a short-term endpoint, and the more meaningful endpoints are prostate cancer-specific survival 
(CSS) and overall survival (OS). In the future, we will investigate and provide the definitive predictive factors of CSS 
and OS.  
 
CONCLUSIONS 
    PI with or without EBRT resulted in excellent short-term biochemical outcomes at all risk groups, especially at 
high-risk group in Japanese PCa patients. Younger age, higher pretreatment PSA, and lower prostate V100 in low-risk 
 
 
patients; higher GS, higher percent positive biopsies, and no HT in intermediate-risk patients; and higher GS and higher 
percent positive biopsies in high-risk patients independently affected biochemical failure. 
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FIGURE CAPTIONS 
Fig. 1. (a) Biochemical freedom from failure (bFFF) in all patients. (b) bFFF by risk group. (c) bFFF by treatment 
modality. 
 
Table 1 Descriptive statistics for patient information 
Factors n Mean SD Minimum Median Maximum Missing 
Age (year) 2,316 68.1 6.4 45 69 89 0 
   Low-risk group 1,028 67.3 6.5 45 68 89 0 
   Intermediate-risk group 1,114 68.6 6.2 51 69 88 0 
   High-risk group 133 69.8 6.2 55 71 84 0 
Pretreatment PSA (ng/ml)* 2,298 8.0 4.1 1.6 6.8 42.0 18 
   Low-risk group 1,028 6.2 1.7 1.6 6.0 9.98 0 
   Intermediate-risk group 1,114 8.8 3.7 1.9 8.1 20.0 0 
   High-risk group 132 14.6 9.0 3.7 11.4 42.0 1 
Percent positive biopsies 2,196 27.5  19.1 3.9  21.4 100 120 
   Low-risk group 975 22.2  14.9 4.2  16.7 100 53 
   Intermediate-risk group 1,058 30.7  19.8 3.9  25 100 56 
   High-risk group 131 39.1  27.8  7.1  33.3  100 2 
 
 
                                                                                                                                                                                   
Prostate volume (ml)† 2,316 25.9 8.2 7.0 25.2 71.0 0 
   Low-risk group 1,028 26.9 8.1 7.3 26.2 60.9 0 
   Intermediate-risk group 1,114 25.4 8.3 8.6 24.8 71 0 
   High-risk group 133 22.9 7.8 7.0 22.2 45.8 0 
Implanted seed number 2,316 68.3 16.6 25 69 120 0 
   Low-risk group 1,028 73.8 14.5 26 75 120 0 
   Intermediate-risk group 1,114 65.0 16.8 28 65 118 0 
   High-risk group 133 53.2 13.0 25 50 99 0 
Activity/seed (MBq) 2,316 13.4 1.0 9.8 13.1 15.3 0 
   Low-risk group 1,028 13.4 1.0 9.8 13.1 15.3 0 
   Intermediate-risk group 1,114 13.4 1.0 10.3 13.1 15.3 0 
   High-risk group 133 13.1 1.1 10.6 12.8 15.3 0 
Total activity (MBq) 2,316 929.3 293.7 244.8 903.9 1,836 0 
   Low-risk group 1,028 1,000.9 267.9 254.5 982.5 1,836 0 
   Intermediate-risk group 1,114 868.8 225.0 334.0 851.5 1,545.8 0 
   High-risk group 133 707.6 236.0 265.5 640 1,514.7 0 
Prostate V100 (%) 2,304 93.9 5.2 56.3 95.2 100 12 
   Low-risk group 1,024 93.5 5.3 63.6 94.7 100 4 
   Intermediate-risk group 1,109 94.2 5.3 56.3 95.6 100 5 
   High-risk group 132 94.4 4.4 78.4 95.4 100.0 1 
Prostate V150 (%) 2,304 62.4 13.5 16.3 63.4 98.1 12 
   Low-risk group 1,024 62.1 13.3 20.8 63.3 92.2 4 
   Intermediate-risk group 1,109 62.6 13.9 16.3 63.3 98.1 5 
   High-risk group 132 63.1 12.9 32.2 63.7 90.7 1 
Prostate D90 (%) 2,304 112.0  15.5  40.1  112.4  191.6 12 
   Low-risk group 1,024 110.9 15.5 40.1  111.0  153.2  4 
   Intermediate-risk group 1,109 112.9  15.6 54.5  113.7  191.6 5 
   High-risk group 132 113.8 15.2  75.5 113.3 161.4 1 
Biologically effective dose (Gy2) 2,305 178.9 28.4 59.0 179.4 289.8 11 
   Low-risk group 1,024 170.6 25.6 59.0 170.0 258.2 4 
   Intermediate-risk group 1,109 184.5 28.8 80.6 187.4 289.8 5 
   High-risk group 133 199.1 25.1 85.5 203.9 255.9 0 
 
 
                                                                                                                                                                                   
SD standard deviation, PSA prostate-specific antigen, VXX the percent volumes receiving XX% of the prescribed dose, 
DXX the values of the minimal dose received by XX% of the volume, RXX the rectal volume in cubic centimeters 
receiving XX% of the prescribed dose 
*Pretreatment PSA was measured before the latest biopsy 
†Prostate volume was measured preimplantation 
 
Table 2 Baseline characteristics of patients 
Factors 
Low-risk group Intermediate-risk group High-risk group Total 
n % n % n % n % 
Gleason score         
6 or less 1,028 100 241 21.6 15 11.3 1,309 56.6 
7 (2+5, 3+4) 0 0 608 54.6 22 16.5 640 27.7 
7 (4+3) 0 0 265 23.8 14 10.5 281 12.2 
8 0 0 0 0 63 47.4 63 2.7  
9 0 0 0 0 19 14.3 19 0.8  
Clinical stage: T stage         
T1c 862 84.0 745 67.2 61 45.9 1,693 73.4 
T2a 164 16.0 203 18.3 31 23.3 403 17.5 
T2b 0 0 106 9.6 15 11.3 121 5.3 
T2c 0 0 55 5.0 10 7.5 66 2.9 
T3a 0 0 0 0 16 12.0 16 0.7 
T3b 0 0 0 0 0 0 2 0.1 
TX 0 0 0 0 0 0 5 0.2 
Clinical stage: N stage         
N0 1028 100 1114 100 133 100 2,299 99.4 
NX 0 0 0 0 0 0 14 0.6 
Clinical stage: M stage         
M0 1,028 100 1,114 100 133 100 2,297 99.3 
MX 0 0 0 0 0 0 16 0.7 
Treatment modalities         
PI 1,011 98.3 701 62.9 23 17.3 1,774 76.6 
 
 
                                                                                                                                                                                   
PI + EBRT 17 1.7 413 37.1 110 82.7 542 23.4 
Hormonal treatment         
Yes 405 39.4 607 54.5 107 80.5 1,138 49.1 
No 623 60.6 507 45.5 26 19.5 1,178 50.9 
PI permanent seed implantation, EBRT external beam radiation therapy 
 
Table 3 Multivariate analyses for biochemical freedom from failure 
Factors 
Univariate analysis Multivariate analysis 
HR 95% CI p HR 95% CI p 
All cases 
Age 0.960 0.936–0.985 0.0016* 0.957 0.932–0.983 0.0012* 
Pretreatment PSA 1.040 1.007–1.074 0.0161* 1.019 0.985–1.054 0.2830 
Gleason score  – – <0.0001* – – 0.0030* 
6 or less Reference Reference 
7 (3+4) 1.353 0.904–2.025 0.1412 1.261 0.826–1.925 0.2828 
7 (4+3), 8 to 10 2.460 1.649–3.670 <0.0001* 2.149 1.380–3.347 0.0007* 
% Positive biopsies  1.016 1.009–1.024 <0.0001* 1.012 1.004–1.020 0.0026* 
Prostate V100 (%) 0.968 0.943–0.995 0.0187 0.970 0.942–0.998 0.0368* 
Low-risk group 
Age 0.928 0.891–0.967 0.0004* 0.926 0.889–0.964 0.0002* 
Pretreatment PSA 1.219 1.044–1.423 0.0123* 1.246 1.069–1.452 0.0048* 
Prostate D90 (%)# 0.983 0.967–0.999 0.0397* – – – 
Prostate V100 (%) 0.944 0.907–0.982 0.0044* 0.936 0.899–0.974 0.0012* 
Intermediate-risk group 
Gleason score  – – 0.0005* – – 0.0005* 
6 or less Reference Reference 
7 (3+4) 2.149 0.958–4.821 0.0634 2.187 0.919–5.205 0.0769 
7 (4+3) 4.258 1.875–9.671 0.0005* 4.538 1.879–10.960 0.0008* 
% Positive biopsies  1.014 1.003–1.024 0.0110* 1.014 1.003–1.025 0.0120* 
Hormonal treatment Yes 0.560 0.353–0.886 0.0133* 0.470 0.290–0.762 0.0022* 
No Reference Reference 
 
 
                                                                                                                                                                                   
High-risk group 
Gleason score  – – 0.0035* – – 0.0329* 
 7 or less  Reference   Reference  
 8 0.503 0.084–3.010 0.4514 0.9587 0.1455–6.317 0.9651 
 9 5.544 1.386–22.170 0.0154* 5.553 1.201–25.670 0.0282* 
% Positive biopsies  1.036 1.015–1.057 0.0007* 1.028 1.006–1.051 0.0120* 
Prostate D90 (%)  1.041 1.003–1.081 0.0327* 1.047 0.9991–1.097 0.0545 
HR hazard ratio, CI confidence interval, other abbreviations as in Table 1. 
*Significant risk factor 
#Prostate D90 is the collinearity factor of prostate V100; therefore, prostate D90 is excluded in the multivariate analysis  
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